2 results match your criteria: "The Strelitz Diabetes Institute[Affiliation]"

The protein kinase C-beta inhibitor, ruboxistaurin, for the treatment of diabetic microvascular complications.

Expert Opin Investig Drugs

December 2005

The Strelitz Diabetes Institute, Eastern Virginia Medical School, Norfolk, VA 23510, USA.

The potential for addressing the underlying biological abnormalities in diabetes has eluded most investigators because of the complex mechanisms underlying the effects of diabetes on the pathogenesis of the complications. Although macrovascular complications, such as myocardial infarction, stroke and gangrene, are only partially attributable to hyperglycaemia and its attendant effects, the microvascular complications including retinopathy, nephropathy and neuropathy are directly related to the degree of hyperglycaemia. In controlled trials, a 22-34% reduction in one of these side effects was achieved for every 1% reduction in glycosylated haemoglobin.

View Article and Find Full Text PDF